Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)

Inclusion Criteria: * Histologically confirmed relapsed or refractory HL or ALCL. * Documented CD30+ expression from either original diagnosis or a tumor biopsy in the relapsed setting. * For patients with HL, subjects are eligible after failure or having declined autologous stem cell transplant or at least two prior multi-agent chemotherapy regimens if they are not autologous stem cell transplant candidates. For patients with ALCL, subjects are eligible after failure of at least one prior multi-agent chemotherapy regimen and if they are not eligible for or have declined autologous stem cell transplant. * Must have received first line chemotherapy. No upper limit for the number of prior therapies. * Patients with prior autologous or allogeneic stem cell transplant are eligible as long as they meet all other criteria. * Measurable or evaluable disease, as defined in 2008 Revised Response Criteria for Malignant Lymphoma(33) * Age \> or = 18 years * ECOG performance status 0,1 or 2 * Patient's must have adequate organ and marrow function as defined below * Absolute neutrophil count \> or = 1,000 (1.0 x 109/L) * Platelets \> or = 50,000 (50 x 109/L) * Total Bilirubin \< or = 1.5 x institutional limits unless documented Gilbert's syndrome (then \< 2.5 x institutional upper limit) * AST (SGOT)/ALT (SGPT) \< or = 2.0 x institutional upper limit of normal (unless known hepatic involvement then \< 3.5 x institutional upper limit) * Creatinine within normal institutional li…